Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1083151.RAhv03e-h2ANjxt7lRBvjw-Y98u_dKFoNQVm0GJQnJVwA130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1083151.RAhv03e-h2ANjxt7lRBvjw-Y98u_dKFoNQVm0GJQnJVwA130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1083151.RAhv03e-h2ANjxt7lRBvjw-Y98u_dKFoNQVm0GJQnJVwA130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1083151.RAhv03e-h2ANjxt7lRBvjw-Y98u_dKFoNQVm0GJQnJVwA130_provenance.
- NP1083151.RAhv03e-h2ANjxt7lRBvjw-Y98u_dKFoNQVm0GJQnJVwA130_assertion description "[Recently, the mTOR inhibitor everolimus was shown to be effective in the treatment of subependymal giant cell astrocytomas (a brain tumor) and renal AMLs (kidney tumors) in TSC patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1083151.RAhv03e-h2ANjxt7lRBvjw-Y98u_dKFoNQVm0GJQnJVwA130_provenance.
- NP1083151.RAhv03e-h2ANjxt7lRBvjw-Y98u_dKFoNQVm0GJQnJVwA130_assertion evidence source_evidence_literature NP1083151.RAhv03e-h2ANjxt7lRBvjw-Y98u_dKFoNQVm0GJQnJVwA130_provenance.
- NP1083151.RAhv03e-h2ANjxt7lRBvjw-Y98u_dKFoNQVm0GJQnJVwA130_assertion SIO_000772 23733802 NP1083151.RAhv03e-h2ANjxt7lRBvjw-Y98u_dKFoNQVm0GJQnJVwA130_provenance.
- NP1083151.RAhv03e-h2ANjxt7lRBvjw-Y98u_dKFoNQVm0GJQnJVwA130_assertion wasDerivedFrom befree-2016 NP1083151.RAhv03e-h2ANjxt7lRBvjw-Y98u_dKFoNQVm0GJQnJVwA130_provenance.
- NP1083151.RAhv03e-h2ANjxt7lRBvjw-Y98u_dKFoNQVm0GJQnJVwA130_assertion wasGeneratedBy ECO_0000203 NP1083151.RAhv03e-h2ANjxt7lRBvjw-Y98u_dKFoNQVm0GJQnJVwA130_provenance.
- befree-2016 importedOn "2016-02-19" NP1083151.RAhv03e-h2ANjxt7lRBvjw-Y98u_dKFoNQVm0GJQnJVwA130_provenance.